In relation to neurological disorders, PP2A has been suggested as a possible treatment target for neurological disorders Alzheimer’s disease (53) and has been recently implicated in Tau pathology of Parkinson’s disease (54). This evidence concerns the gene PTPA and early-onset autosomal dominant Alzheimer disease.